B. Riley Predicts Lineage Cell Therapeutics FY2029 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Equities research analysts at B. Riley reduced their FY2029 earnings per share estimates for shares of Lineage Cell Therapeutics in a report issued on Friday, May 23rd. B. Riley analyst M. Mamtani now expects that the company will post earnings of $0.16 per share for the year, down from their prior estimate of $0.20. B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share.

A number of other equities analysts have also recently commented on LCTX. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $4.20.

Lineage Cell Therapeutics Stock Performance

Shares of Lineage Cell Therapeutics stock opened at $0.70 on Monday. The stock has a market cap of $154.01 million, a price-to-earnings ratio of -5.82 and a beta of 1.21. The stock has a 50 day moving average price of $0.47 and a 200-day moving average price of $0.62. Lineage Cell Therapeutics has a one year low of $0.37 and a one year high of $1.15.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Broadwood Capital Inc. raised its position in Lineage Cell Therapeutics by 18.9% during the 1st quarter. Broadwood Capital Inc. now owns 49,560,992 shares of the company’s stock valued at $22,382,000 after purchasing an additional 7,894,737 shares in the last quarter. Royal Bank of Canada raised its position in Lineage Cell Therapeutics by 1,578.9% during the 1st quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock valued at $237,000 after purchasing an additional 497,168 shares in the last quarter. Comerica Bank raised its position in Lineage Cell Therapeutics by 275.0% during the 1st quarter. Comerica Bank now owns 3,000,000 shares of the company’s stock valued at $1,355,000 after purchasing an additional 2,200,000 shares in the last quarter. Cookson Peirce & Co. Inc. bought a new stake in Lineage Cell Therapeutics during the 1st quarter valued at $113,000. Finally, Nuveen LLC bought a new stake in Lineage Cell Therapeutics during the 1st quarter valued at $233,000. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.